Vitrolife AB (CHIX:VITRS) GF Value Rank: 4 (As of Aug. 05, 2026) — 33% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:VITRS Vitrolife AB CHIX:VITRS
80 GF Score
Price kr86.38
GF Value kr185.92
! 6 Warning Signs
View Full Analysis

What is Vitrolife AB GF Value Rank?

Vitrolife AB CHIX:VITRS 80 GF Value Rank is 4 as of Aug. 05, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates CHIX:VITRS with a GF Score™ of 80/100 and a GF Value™ of kr185.92. The stock has 6 warning signs investors should review.

Vitrolife AB has the GF Value Rank of 4.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Vitrolife AB GF Value Rank Related Terms

CHIX:VITRS vs ABT, SYK, MDT: GF Value Rank Comparison

For the Medical Devices subindustry, Vitrolife AB's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vitrolife AB GF Value Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Vitrolife AB's GF Value Rank falls into.


CHIX:VITRS
80GF Score
Vitrolife AB CHIX:VITRS
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 4 mean?
Vitrolife AB (CHIX:VITRS) has a GF Value Rank of 4 as of Aug. 05, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Vitrolife AB and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Vitrolife AB's GF Value Rank has ranged from 1.00 to 10.00.
Is Vitrolife AB's GF Value Rank too high?
Vitrolife AB's current GF Value Rank of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Vitrolife AB has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's GF Value Rank compare to ABT and SYK?
Vitrolife AB's GF Value Rank of 4 can be compared against companies in the Medical Devices & Instruments industry. Historically, Vitrolife AB's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Medical Devices & Instruments company?
A good GF Value Rank depends on the Medical Devices & Instruments industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Vitrolife AB and its competitors. Vitrolife AB's current GF Value Rank is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Vitrolife AB (CHIX:VITRS) has a current GF Value Rank of 4. The stock's GF Value™ is kr185.92, compared to a current price of kr86.38 — trading 53.5% below its estimated fair value. The current GF Value Rank is 4, which is 33% below median its 10-year median of 6.00. Vitrolife AB's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current GF Value Rank is 4 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?

Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued. The current stock price of kr86.38 is trading 53.5% below its estimated GF Value™ of kr185.92.

Key valuation signals for CHIX:VITRS:

  • GF Value Rank: 4 (33% below median its 10-year median of 6.00)
  • GF Value™: kr185.92 vs. price of kr86.38 (53.5% below fair value)
  • GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vitrolife AB Business Description

Address Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
80GF Score

Get the complete analysis for CHIX:VITRS

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr86.38
Price
kr185.92
GF Value